Open AccessChallenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy
Author(s) -
Yuqi Zhou,
Colby R. Maldini,
Julie K. Jadlowsky,
James L. Riley
Publication year - 2021
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiaa223
Subject(s) - immunology , human immunodeficiency virus (hiv) , medicine , t cell , antiretroviral therapy , viral replication , immune system , regimen , cell therapy , cell , adoptive cell transfer , virology , virus , viral load , biology , genetics
HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.